Selecta is working on two antigen-specific SVP applications covering immune tolerance and immuno-stimulatory vaccines.
Selecta Biosciences' proprietary Synthetic Vaccine Particle (SVP) technology encapsulates an immunomodulator in biodegradable particles to selectively modulate an immune response in an antigen‑specific manner. Depending on the type of immunomodulator encapsulated in the SVP, Selecta Biosciences' technology is designed to induce either a:
Selecta Biosciences' lead product candidate, SEL‑212, is a therapeutic enzyme designed to be the first non‑immunogenic biologic therapy for the treatment of refractory and tophaceous gout, each a painful and debilitating disease with unmet medical need. Selecta Biosciences is also applying its SVP technology to antigen-specific immune tolerance to gene therapy and the treatment of autoimmune diseases, allergies and marketed biologics. Selecta Biosciences has a collaboration with Genethon to develop an adeno-associated virus (AAV)-based gene therapy designed to mitigate the formation of ADAs to enable repeated administration, and three collaborations with Sanofi to research novel SVP products for the treatment of a life-threatening food allergy, celiac disease and type 1 diabetes.
Synthetic Vaccine Particles (SVP) immune stimulation products contain encapsulated and/or surface antigens as well as a toll like receptor (TLR) agonists adjuvant to activate the immune response. Selecta Biosciences has early‑stage research programs for therapeutic vaccines for human papilloma virus-associated cancers and for antibody‑based vaccine programs for nicotine addiction and malaria. To date, these programs are primarily financed through grants.